Catalyst overview
Research summary
This catalyst tracks a Phase 1 data readout for FT836 (CAR T Cell) in Multiple Myeloma. The expected timing is based on the latest available company guidance and may change.
12/08/25:- Preclinical FT836 CAR T data at ASH 2025 showed MICA/B and CD38 targeting for multiple myeloma. 02/26/26:- Early FT836 Phase 1 CRC cohort shows >50% CEA drop; additional clinical data updates in H2 2026. 05/13/26:- FDA cleared IIT of FT836 in combination with daratumumab for multiple myeloma; patient treatment expected Mid-2026. 08/13/26:- FDA-cleared investigator-initiated FT836 plus daratumumab trial in multiple myeloma was reiterated. Clinical data will be updated in H2 2026.
Verification
Confirm timing and program details against the company announcement or filing.